Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma
Cell-free DNA Oncogene Copy Number as a Surrogate Molecular Biomarker in ALK/MYCN-coamplified Neuroblastoma
复制标题
DOI：
10.1097/mph.0000000000001720
复制
发表时间：
2021-03-01
影响因子：
1.2
通讯作者：
Heike, Toshio
中科院分区：
文献类型：
--
作者：
Kobayashi, Kenichiro;Mizuta, Shumpei;Heike, Toshio
神经母细胞瘤侵袭性亚克隆的继发性扩增和/或进化与疾病进展和化疗耐药性有关，在治疗期间跟踪克隆的变化是很重要的。无细胞（cf） DNA分析，即液体活检，可以检测肿瘤细胞的基因组变化，而无需外科手术。在本报告中，我们发现基于序列聚合酶链反应的cf DNA神经母细胞瘤原癌基因定量足够敏感，可以评估ALK/ mycn共扩增的神经母细胞瘤的侵袭性细胞特征，并强调cf DNA分析有望作为晚期神经母细胞瘤的可靠分子标志物。
Secondary expansion and/or evolution of aggressive subclones are associated with the disease progression and resistance to chemotherapy in neuroblastoma, and it is important to track the clonal changes during the treatment period. Cell-free (cf) DNA analysis, namely liquid biopsy, can detect the genomic change of tumor cells without surgical procedures. In this report, we showed that serial polymerase chain reaction-based cf DNA neuroblastoma proto-oncogene quantification is sensitive enough to evaluate the aggressive cellular characteristics of ALK/MYCN-coamplified neuroblastoma and stressed the promise of cf DNA analyses as a reliable molecular marker in advanced neuroblastoma.